Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Capivasertib→

Capivasertib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1143532-39-1
Molecular formula
C21H25ClN6O2
Molecular weight
428.9 g/mol
Drug class
ATP-competitive pan-AKT kinase inhibitortargeted antineoplastic
Mechanism of action
Inhibits all three AKT isoforms (AKT1, AKT2 and AKT3), reducing signalling through the PI3K/AKT pathway and downstream pathways involved in tumour-cell growth and survival.
Indications / reported uses
  • In combination with fulvestrant for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations detected by an FDA-authorised test after progression on or recurrence following endocrine-based therapy
  • In combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer under the US FDA indication approved June 12 2026

Sources: US DailyMed — TRUQAP label, updated September 16 2026 · US FDA — Capivasertib approval for PTEN-deficient prostate cancer, June 12 2026 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Capivasertib Environmental Risk Assessment (ERA) (the Capivasertib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.